China approves 3rd COVID-19 vaccine for clinical trials


Beijing: China has approved its third coronavirus vaccine for the second phase of clinical trials as it reported 12 new COVID-19 cases, taking the total number of infections in the country to 82,816.

China has approved three coronavirus vaccines, including the one developed by Chinese military, the People's Liberation Army (PLA) for clinical trials.

An 'inactivated' vaccine developed by Wuhan Institute of Biological Products under the China National Pharmaceutical Group (Sinopharm) and the Wuhan Institute of Virology (WIV) started its clinical trials, state-run 'Xinhua' news agency reported.

An 'inactivated' vaccine consists of virus particles, bacteria, or other pathogens that have been grown in culture and then lose disease producing capacity.

In contrast, live vaccines use pathogens that are still alive.

WIV has been in the eye of the storm in recent weeks as US President Donald Trump and top American officials alleged that the coronavirus may have escaped from there and demanded a probe into it.

An official of the WIV denied it, terming the allegation 'entirely based on speculation'.

Research Desk/